Antiretroviral therapy is the principal cause of tuberculosis decline in southern and eastern Africa
作者： Christopher Dye , Brian G. Williams
DOI: 10.1101/477158
关键词: Antiretroviral therapy 、 Disease 、 Coinfection 、 Human immunodeficiency virus (HIV) 、 Incidence (epidemiology) 、 Environmental health 、 Medicine 、 Tuberculosis 、 Mycobacterium tuberculosis 、 Isoniazid
摘要: The incidence of tuberculosis (TB) in southern and eastern Africa was driven sharply upwards during 1980s 1990s by coinfection with Mycobacterium the human immunodeficiency virus (HIV). Although drug treatments for TB infection (isoniazid preventive therapy) disease (combinations drugs) can reduce if implemented effectively, we find that antiretroviral therapy (ART) HIV principal cause decline 12 worst affected African countries between 2003 2016. ART prevented up to 1.92 million HIV-positive cases, or 17.3 percent total number expected. In these countries, over period 2003-16, made most significant contribution towards achieving international targets reduction incidence.
sci-hub.st 参考文章(25)
Christopher Dye, The Population Biology of Tuberculosis ,(2015)
In Search of Prosperity: Analytic Narratives on Economic Growth Princeton University Press. ,(2003) , 10.1515/9781400845897
Christopher Akolo, Ifedayo Adetifa, Sasha Shepperd, Jimmy Volmink, None, Treatment of latent tuberculosis infection in HIV infected persons Cochrane Database of Systematic Reviews. ,vol. 2010, ,(2010) , 10.1002/14651858.CD000171.PUB3
Luuk Gras, Anouk M Kesselring, James T Griffin, Ard I van Sighem, Christophe Fraser, Azra C Ghani, Frank Miedema, Peter Reiss, Joep M A Lange, Frank de Wolf, CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. Journal of Acquired Immune Deficiency Syndromes. ,vol. 45, pp. 183- 192 ,(2007) , 10.1097/QAI.0B013E31804D685B
Keren Middelkoop, Linda-Gail Bekker, Landon Myer, Leigh F Johnson, Matthew Kloos, Carl Morrow, Robin Wood, Antiretroviral therapy and TB notification rates in a high HIV prevalence South African community. Journal of Acquired Immune Deficiency Syndromes. ,vol. 56, pp. 263- 269 ,(2011) , 10.1097/QAI.0B013E31820413B3
A Reid, AD Grant, RG White, C Dye, Emilia Vynnycky, K Fielding, G Churchyard, Y Pillay, None, Accelerating progress towards tuberculosis elimination: the need for combination treatment and prevention. International Journal of Tuberculosis and Lung Disease. ,vol. 19, pp. 5- 9 ,(2015) , 10.5588/IJTLD.14.0078
Taraz Samandari, Tefera B Agizew, Samba Nyirenda, Zegabriel Tedla, Thabisa Sibanda, Nong Shang, Barudi Mosimaneotsile, Oaitse I Motsamai, Lorna Bozeman, Margarett K Davis, Elizabeth A Talbot, Themba L Moeti, Howard J Moffat, Peter H Kilmarx, Kenneth G Castro, Charles D Wells, 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. The Lancet. ,vol. 377, pp. 1588- 1598 ,(2011) , 10.1016/S0140-6736(11)60204-3
Brian G Williams, Christopher Dye, Antiretroviral Drugs for Tuberculosis Control in the Era of HIV/AIDS Science. ,vol. 301, pp. 1535- 1537 ,(2003) , 10.1126/SCIENCE.1086845
Leigh F. Johnson, Joel Mossong, Rob E. Dorrington, Michael Schomaker, Christopher J. Hoffmann, Olivia Keiser, Matthew P. Fox, Robin Wood, Hans Prozesky, Janet Giddy, Daniela Belen Garone, Morna Cornell, Matthias Egger, Andrew Boulle, , Life Expectancies of South African Adults Starting Antiretroviral Treatment: Collaborative Analysis of Cohort Studies PLoS Medicine. ,vol. 10, pp. e1001418- ,(2013) , 10.1371/JOURNAL.PMED.1001418
Molebogeng X Rangaka, Robert J Wilkinson, Andrew Boulle, Judith R Glynn, Katherine Fielding, Gilles van Cutsem, Katalin A Wilkinson, Rene Goliath, Shaheed Mathee, Eric Goemaere, Gary Maartens, Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial The Lancet. ,vol. 384, pp. 682- 690 ,(2014) , 10.1016/S0140-6736(14)60162-8